Among these, checkpoint inhibition and targeted therapies, such as Poly (ADP-ribose) polymerase (PARP) inhibition, are of interest with the current understanding of the molecular biology of endometrial cancer. Here, we focus on the molecular basis of checkpoint and PARP inhibition in endometrial ...
- 《Breast Cancer Research》 被引量: 315发表: 2011年 Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. The most common carcinomas metastatic to the ovary that mimic ovarian primaries are colonic adenocarcinomas and endometrial carcinomas. Conventional histoc... CCAP...
DB-1303 is a topoisomerase-1 inhibitor in which phase 1/2 trial (NCT05150691) data have shown the treatment to be well-tolerated. In an already heavily pretreated population of patients with breast cancer, DB-1303 elicited encouraging antitumor activity. In the phase 1/2 study, 85 patients w...
The diagnoses included adenocarcinoma of the lung (three) and advanced colorectal carcinoma (three), and one patient each had breast, endometrial, nasopharyngeal, and chorioembryonal carcinoma. In addition to surgical resections, all patients had received previous therapy with either irradiation (two),...
Beyond its early documented activity in relapsed ovarian cancer (Eisenhauer et al, 1994), there are a small number of studies confirming its activity in advanced endometrial carcinoma (Lissoni et al, 1996). Single-agent paclitaxel has shown an initial 17% activity in advanced cervical cancer at...
Erlotinib (Tarceva™, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its activity in patients with metastatic colorectal cancer. In all, 38 patients with metastatic colo
Endometrial cancer (EC) is the sixth most prevalent cancer among women, with 417,000 new cases reported annually worldwide [1]. The global incidence of EC has risen by 21% since 2008, attributed to extended life expectancy and the increasing prevalence of obesity [2]. The majority of patien...